Funding for this research was provided by:
Institut National Du Cancer (11862)
Received: 27 May 2020
Accepted: 20 August 2020
First Online: 3 September 2020
Ethics approval and consent to participate
: UNICANCER R&D, the sponsor of the PRODIGE 5/ACCORD 17 trial (ExternalRef removed Identifier: NCT00861094), provided permission for the data base access. All participants of the PRODIGE 5/ACCORD 17 trial provided written informed consent. Patient consent was not required for this study as we performed a secondary analysis of existing data.
: Not applicable
: The authors have declared no conflicts of interest.